DR. CELESTE ANN WILCOX MD PHD NPI 1386688232

NPI Details

DR. Celeste Ann Wilcox, MD, PHD is a medical oncology internal medicine in Paris, TX with 31 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Celeste Ann Wilcox, MD, PHD NPI is 1386688232. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

3550 NE LOOP 286
PARIS, TX
ZIP 75460-004
Phone: (903) 785-0031
Fax: (903) 784-6755

The NPI 1386688232 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Ferritin (blood protein) level (HCPCS:82728)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session (HCPCS:G6015)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev (HCPCS:G6013)
• Ct scan of chest with contrast (HCPCS:71260)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Blood creatinine level (HCPCS:82565)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Ct scan of chest without contrast (HCPCS:71250)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Unclassified drugs (HCPCS:J3490)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev (HCPCS:G6012)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Drawing of blood for a medical problem (HCPCS:99195)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• Red blood count, automated test (HCPCS:85045)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Ct scan of abdomen with contrast (HCPCS:74160)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)

The enumeration date for this NPI number is 6/15/2006 and was last updated on 3/7/2016.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.